Edlira Horjeti

Edlira Horjeti

Auto-generated profile, based on publicly available information

Edlira Horjeti

Department of Urology, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JAJack R. Andrews
Jack R. Andrews
YKYohan Kim
Yohan Kim
EHEdlira Horjeti
Edlira Horjeti
AAAli T. Arafa
Ali T. Arafa
HGHeather Gunn
Heather Gunn
Fabrice LucienFabrice Lucien
Fabrice Lucien
Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA+) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA+EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA+EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA+EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA+EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA+EV was predictive of benefit from SABR (P = 0.012). Conclusions: PSMA+EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA+EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.

17 March 2025
Verified
Other
Open access
JAJack R. Andrews
Jack R. Andrews
YKYohan Kim
Yohan Kim
EHEdlira Horjeti
Edlira Horjeti
AAAli T. Arafa
Ali T. Arafa
HGHeather Gunn
Heather Gunn
Fabrice LucienFabrice Lucien
Fabrice Lucien
Association of baseline PSMA+EV levels with radiographical PFS in ORIOLE SABR and observation arms

17 March 2025
Verified
Other
Open access
JAJack R. Andrews
Jack R. Andrews
YKYohan Kim
Yohan Kim
EHEdlira Horjeti
Edlira Horjeti
AAAli T. Arafa
Ali T. Arafa
HGHeather Gunn
Heather Gunn
Fabrice LucienFabrice Lucien
Fabrice Lucien
Progression-free survival stratified by number of lesions treated

17 March 2025
Verified
Other
Open access
JAJack R. Andrews
Jack R. Andrews
YKYohan Kim
Yohan Kim
EHEdlira Horjeti
Edlira Horjeti
AAAli T. Arafa
Ali T. Arafa
HGHeather Gunn
Heather Gunn
Fabrice LucienFabrice Lucien
Fabrice Lucien
Purpose:Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA+) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts.Experimental Design:Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA+EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA+EV and PSA levels with clinical outcomes.Results:In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA+EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA+EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA+EV was predictive of benefit from SABR (P = 0.012).Conclusions:PSMA+EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA+EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.

17 March 2025
Verified
Other
Open access
JAJack R. Andrews
Jack R. Andrews
YKYohan Kim
Yohan Kim
EHEdlira Horjeti
Edlira Horjeti
AAAli T. Arafa
Ali T. Arafa
HGHeather Gunn
Heather Gunn
Fabrice LucienFabrice Lucien
Fabrice Lucien
Progression-free survival stratified by baseline PSA and PSMA+EV

17 March 2025
Verified
Other
Open access
JAJack R. Andrews
Jack R. Andrews
YKYohan Kim
Yohan Kim
EHEdlira Horjeti
Edlira Horjeti
AAAli T. Arafa
Ali T. Arafa
HGHeather Gunn
Heather Gunn
Fabrice LucienFabrice Lucien
Fabrice Lucien
Association of baseline PSA levels with biochemical and radiographic PFS in ORIOLE SABR and observation arms